Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

OliX Pharmaceuticals

Biotech & Life Sciences · Suwon, South Korea · Founded 2010 · IPO 2018 Unicorn

Asymmetric RNAi therapeutics for dermal and ophthalmic diseases

Valuation
$2.82B
Market cap · May/2026
Revenue
$12M
Latest reported FY

Global footprint

Where OliX Pharmaceuticals has talent and traffic

Workforce by country
2 countries with
team presence
🇰🇷 South Korea57.2%
🇺🇸 United States42.8%
2 countries shown
Web traffic by country
29K monthly visits
across markets
🏳️ Korea107.6%
🏳️ Republic of3.4%
🇺🇸 United States0%
Top 3 markets shown

Patent intelligence

$49M patent portfolio · 36 active families

Estimated portfolio value
$49M
1.7% of market cap · 5.6× smaller than top peer argenx ($275M)
36 active patent families
Where OliX Pharmaceuticals innovates Molecular biologyRNAMoietyNucleotideMacromolecule

Where OliX Pharmaceuticals concentrates vs peers

Each axis is a top-10 topic across OliX Pharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about OliX Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about OliX Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See OliX Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.